Breaking News

Tweet TWEET

Biotech Firms Participate in Upcoming Conferences; Sees Steady Numbers around Thanksgiving - Research Report on BioMarin,

Biotech Firms Participate in Upcoming Conferences; Sees Steady Numbers around
  Thanksgiving - Research Report on BioMarin, Halozyme, PDL BioPharma, Anika
                           Therapeutics, and Exelis

PR Newswire

NEW YORK, December 3, 2013

NEW YORK, December 3, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting BioMarin
Pharmaceutical Inc. (NASDAQ: BMRN), Halozyme Therapeutics, Inc. (NASDAQ:
HALO), PDL BioPharma Inc. (NASDAQ: PDLI),

Anika Therapeutics, Inc. (NASDAQ: ANIK), and Exelixis, Inc. (NASDAQ: EXEL).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

BioMarin Pharmaceutical Inc. Research Report

On November 27, 2013, BioMarin Pharmaceutical Inc.'s (BioMarin) stock rose
0.28% to $70.73 at the end of trading. Over the previous three trading
sessions, BioMarin's shares dipped 0.44% when compared to the Nasdaq
composite, which gained 1.33% during the same period. In another release dated
November 26, 2013, the Company announced that its Executive Vice President and
CFO Dan Spiegelman will present at the Deutsche Bank 2013 BioFest Conference
on Tuesday, December 3, 2013 at 9:35 a.m. ET. The Full Research Report on
BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9b6c_BMRN

Halozyme Therapeutics, Inc. Research Report

On November 26, 2013, Halozyme Therapeutics, Inc. (Halozyme) announced its
participation at the upcoming Piper Jaffray Healthcare Conference on Tuesday,
December 3, 2013. Halozyme's President and CEO Gregory I. Frost will provide a
corporate overview at 12:00 p.m. ET/9:00 a.m. PT. The presentation will be
webcast through the Investors section of the Company's website. The Full
Research Report on Halozyme Therapeutics, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/ea1b_HALO

PDL BioPharma Inc. Research Report

On November 27, 2013, shares of PDL BioPharma Inc. (PDL BioPharma) rose 1.15%
to end trading at $9.66 per share. Over the previous three trading sessions,
PDL BioPharma's shares gained 2.99% while the Nasdaq composite also gained
1.33% during the same period. The Full Research Report on PDL BioPharma Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/066b_PDLI

Anika Therapeutics, Inc. Research Report

On November 27, 2013, Anika Therapeutics, Inc.'s (Anika Therapeutics) shares
stood at $34.30 at the close, indicating a 1.27% increase. Anika Therapeutics'
shares rose 12.87% over the previous three trading sessions while the Nasdaq
composite gained 1.33% during the same period. The Full Research Report on
Anika Therapeutics, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ae5d_ANIK

Exelixis, Inc. Research Report

On November 26, 2013, Exelixis, Inc. (Exelis) announced that its President and
CEO, Michael M. Morrissey, Ph.D., will present at the 25th Annual Piper
Jaffray Healthcare Conference at 10:30 a.m. EST/7:30 a.m. PST on Tuesday,
December 3, 2013 in New York. Dr. Morrissey will review the Company's
development plans and priorities for cabozantinib. Dr. Morrissey will also
discuss the Company's corporate strategy and financial outlook, and provide a
general business update. The Full Research Report on Exelixis, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/73be_EXEL

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)